Short-horizon event study estimation with a STAR model and real contaminated events

被引:3
|
作者
Andreou P.C. [1 ,2 ]
Louca C. [1 ,2 ]
Savva C.S. [1 ,3 ]
机构
[1] Department of Commerce, Finance and Shipping, Cyprus University of Technology, 115, Spyrou Araouzou Street, Lemesos
[2] Durham University Business School, Mill Hill Lane, Durham
[3] Centre for Growth and Business Cycle Research, University of Manchester, Manchester
关键词
Contaminated events; Event studies; Markov switching regression model; Smooth Transition Auto Regressive model; Test statistics;
D O I
10.1007/s11156-015-0515-3
中图分类号
学科分类号
摘要
We propose a test statistic for nonzero mean abnormal returns based on a Smooth Transition Auto Regressive (STAR) model specification. Estimation of STAR takes into account the probability of contaminated events that could otherwise bias the parameters of the market model and thus the specification and power of the test statistic. Using both simulated and real stock returns data from mergers and acquisitions, we find that the STAR test statistic is robust to contaminated events occurring in the estimation window and in the presence of event-induced increase in return variance. Under the STAR test statistic the true null hypothesis is rejected at appropriate levels. Moreover, it exhibits the highest levels of power when compared with other test statistics that are widely and routinely applied in short-horizon event studies. © 2015, Springer Science+Business Media New York.
引用
收藏
页码:673 / 697
页数:24
相关论文
共 50 条
  • [11] A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
    Qi, Yiming
    Li, Jing
    Lin, Sisi
    Wu, Shuangshuang
    Chai, Kequn
    Jiang, Xin
    Qian, Jiancheng
    Jiang, Cheng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [12] A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant
    Wen, Heli
    Ding, Yitian
    Chen, Feichi
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [13] Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone
    Huang, Youqi
    Gao, Hongjin
    Lin, Yuze
    Chen, Xiaowen
    Chen, Mingyu
    Chen, Min
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [14] A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil
    Wang, Yan
    Zhao, Bin
    Yang, Haiyan
    Wan, Zheng
    ANDROLOGY, 2024, 12 (04) : 785 - 792
  • [15] A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib
    Zhang, Xinyue
    Li, Rongrong
    Li, Yanrong
    He, Lu
    Hou, Encun
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [16] Responses of chronically contaminated biofilms to short pulses of diuron -: An experimental study simulating flooding events in a small river
    Tlili, Ahmed
    Dorigo, Ursula
    Montuelle, Bernard
    Margoum, Christelle
    Carluer, Nadia
    Gouy, Veronique
    Bouchez, Agnes
    Berard, Annette
    AQUATIC TOXICOLOGY, 2008, 87 (04) : 252 - 263
  • [17] A Numerical Model to Study Pulsing Soil Flushing: Validation and Application to a Real Contaminated Soil
    Luciano, Antonella
    Viotti, Paolo
    Mancini, Giuseppe
    BOSICON 2012: 3RD INTERNATIONAL CONFERENCE ON CONTAMINATED SITES REMEDIATION, 2012, 28 : 151 - 156
  • [18] A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
    Menglin Guo
    Yamin Shu
    Guosong Chen
    Juan Li
    Feie Li
    Scientific Reports, 12
  • [19] A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
    Hai, Le
    Wu, Jiaojiao
    Pan, Xiaohong
    Yin, Weicheng
    Wu, Zhishan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2025, 34 (01)
  • [20] A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
    Yin, Yanchao
    Shu, Yamin
    Zhu, Junru
    Li, Feie
    Li, Juan
    SCIENTIFIC REPORTS, 2022, 12 (01)